INFORMATION

2018.9.13
Boehringer Ingelheim, UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce conclusion of a collaborative research and development deal to develop a gene therapy for cystic fibrosis based on the vector technology developed by ID Pharma, I’rom Group subsidiary.
2018.8.22
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Elpis Biomed.
2018.8.21
I’rom Group concludes a strategic partnership agreement with Beroni Group.
2018.6.22
ID Pharma granted EU patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2018.5.28
I’rom Group concludes a strategic partnership agreement with Japanese Bio company Dendrix.
2018.5.11
Summary of Business Results for the Fiscal Year Ended March 31, 2018 [Japan GAAP] (Consolidated)
2018.2.8
Summary of Business Results for the Third Quarter Ended December 31, 2017 [Japan GAAP] (Consolidated)
2018.2.2
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based QurAlis Corporation.
2018.1.29
Establishment of a Subsidiary in Hong Kong
2018.1.9
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based Q-State Biosciences, Inc..
2018.1.29
Establishment of a Subsidiary in Hong Kong
2017.11.9
I’rom Group announces interim dividends from surplus, with a record date of September 30, 2017.
2017.10.17
I’rom Group concludes a partnership agreement with OKEIOS, a subsidiary of OKWAVE.
2017.8.23
IDT Australia announces the completion of the CMAX transaction.
2017.8.23
I’rom Group completes acquisition of all the shares in CMAX.
2017.3.31
I’rom Group concludes a share exchange agreement with Ethic Co., Ltd.
2017.1.16
UPDATE: From Management
2016.12.15
Our English website is renewed.
2016.10.13
I’rom Group issues its 9th stock acquisition rights (with an amended exercise price) through third party allotment and concludes an agreement (Commit Issue) for a third-party allotment of stock acquisition rights
2016.6.13
I’rom Group outside director Mr. Yoshiyuki Nagai receives The Order of the Sacred Treasure, Gold Rays with Neck Ribbon in spring 2016
2018.9.13
Boehringer Ingelheim, UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce conclusion of a collaborative research and development deal to develop a gene therapy for cystic fibrosis based on the vector technology developed by ID Pharma, I’rom Group subsidiary.
2018.8.22
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Elpis Biomed.
2018.8.21
I’rom Group concludes a strategic partnership agreement with Beroni Group.
2018.6.22
ID Pharma granted EU patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2018.5.28
I’rom Group concludes a strategic partnership agreement with Japanese Bio company Dendrix.
2018.2.2
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based QurAlis Corporation.
2018.1.9
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with US-based Q-State Biosciences, Inc..
2017.11.27
ID Pharma, Acting in the Role of In-Country Clinical Caretaker, Submits CTN for US Company DiscGenics’ IDCT-001 Clinical Trial
2017.11.13
ID Pharma granted Chinese patent for the technology regarding production of functional classical brown adipocytes from human pluripotent stem cells.
2017.7.11
ID Pharma concluded an iPS Cell Generation Technology Licensing Agreement with UK-based Axol Bioscience.
2018.5.11
Summary of Business Results for the Fiscal Year Ended March 31, 2018 [Japan GAAP] (Consolidated)
2018.2.8
Summary of Business Results for the Third Quarter Ended December 31, 2017 [Japan GAAP] (Consolidated)
2017.11.9
Summary of Business Results for the Second Quarter Ended September 30, 2017 [Japan GAAP] (Consolidated)
2017.8.9
Summary of Business Results for the First Quarter Ended June 30, 2017 [Japan GAAP] (Consolidated)
2017.5.12
Summary of Business Results for the Fiscal Year Ended March 31, 2017 [Japan GAAP] (Consolidated)
2017.2.13
Summary of Business Results for the Third Quarter Ended December 31, 2016 [Japan GAAP] (Consolidated)
2016.11.11
Summary of Business Results for the Second Quarter Ended September 30, 2016 [Japan GAAP] (Consolidated)
2016.8.10
Summary of Business Results for the First Quarter Ended June 30, 2016 [Japan GAAP] (Consolidated)
2016.5.13
Summary of Business Results for the Fiscal Year Ended March 31, 2016 [Japan GAAP] (Consolidated)
2016.2.10
Summary of Business Results for the Third Quarter Ended December 31, 2015 [Japan GAAP] (Consolidated)
cmax
pagetop